secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001104659-23-030356
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals closes $2.9M registered direct offering of common stock and warrants
--------------------------------------------------------------------------------

- Gross proceeds of ~$2.9M from sale of 3,766,666 shares and 3,766,666 warrants at $0.75 per unit.
- All investors are existing holders; shares restricted from transfer for 6 months.
- Warrants exercisable at $0.75 starting 6 months after issuance, expiring in 5 years.
- Proceeds to fund working capital and initiate national treatment protocol for NRX-101 for bipolar depression with suicidal risk.
- Offering closed on March 9, 2023 under existing effective S-3 registration statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923030356/0001104659-23-030356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923030356/tm238149d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-030356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer